ライフサイエンスコーパス: lipoprotein

1 s well as cellular uptake of cholesterol and lipoprotein.

2 l cysteine, generating a mature, triacylated lipoprotein.

3 y and intestinally derived triglyceride-rich lipoproteins.

4 activation of host macrophages by bacterial lipoproteins.

5 at assemble the barrier requires one or more lipoproteins.

6 tion-fibrinolytic systems, as well as plasma lipoproteins.

7 ithout compromising trafficking of essential lipoproteins.

8 misfolding by binding to plasma high-density lipoproteins.

9 prevent lethal accumulation of mislocalized lipoproteins.

10 ynthetic lipoprotein (fibroblast-stimulating lipoprotein 1 [FSL-1]) or lipopolysaccharide (LPS) signi

11 re 51.2%; body mass index 33.8%; low-density lipoprotein 31.4%; and waist-to-hip ratio 29.7%.

12 xposure of monocytes to oxidized low-density lipoprotein, 7-ketocholesterol, phorbol 12-myristate 13-

13 f PCSK9 also results in reductions of plasma lipoprotein (a) levels.

14 y lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylomicron remnants.

15 RATIONALE: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like

16 onfirmed that plasma-derived and recombinant lipoprotein(a) as well as purified recombinant apo(a) va

17 ent in LPA KIV2 repeats after adjustment for lipoprotein(a) concentration and conventional lipid conc

18 s mendelian randomisation study, we measured lipoprotein(a) concentration and determined apolipoprote

19 apolipoprotein(a) isoform size and increased lipoprotein(a) concentration are independent and causal

20 with all-cause mortality (highest tertile of lipoprotein(a) concentration in plasma 0.95, 0.81-1.11 a

21 We tested associations of tertiles of lipoprotein(a) concentration in plasma and two LPA singl

22 ller apolipoprotein(a) isoform size, but not lipoprotein(a) concentration, and rs3777392 as a variant

23 , and rs3777392 as a variant associated with lipoprotein(a) concentration, but not apolipoprotein(a)

24 mate whether apolipoprotein(a) isoform size, lipoprotein(a) concentration, or both were causally asso

25 Lipoprotein(a) concentrations in plasma are associated w

26 f coronary heart disease was associated with lipoprotein(a) concentrations in plasma in the highest t

27 Whether lipoprotein(a) concentrations or LPA genetic variants pr

28 Results for plasma lipoprotein(a) concentrations were validated in five ind

29 In participants for whom KIV2 repeat and lipoprotein(a) data were available, the OR for myocardia

30 For two traits, lipoprotein(a) levels and neutrophil count, aggregate te

31 nsferase; and, in women, C-reactive protein, lipoprotein(a), and glycated hemoglobin levels.

32 ntithrombin, factors VIII/IX/XI, fibrinogen, lipoprotein(a), homocysteine, lupus anticoagulant, antic

33 poprotein through a disulfide bridge to form lipoprotein(a).

34 ing the periplasmic PDZ-protease Prc and the lipoprotein adaptor NlpI contributes to PG enlargement b

35 promoted cholesterol efflux to acceptor (apo)lipoprotein and human serum, while loss of TSPO resulted

36 a) [Lp(a)] is a low-density lipoprotein-like lipoprotein and important cardiovascular risk factor who

37 Reductions in intermediate-density lipoprotein and LDL production also contributed to the d

38 inflammation induced by oxidized low-density lipoprotein and promoting apoptotic cell clearance.

39 ubsequently binds the outer membrane-derived lipoproteins and LPS to inhibit TLR2 and TLR4 activation

40 erogenesis such as oxidative modification of lipoproteins and phospholipids, endothelial cell activat

41 mice, which show impaired clearing of plasma lipoproteins and spontaneously develop atherosclerosis,

42 namely, fibrinogen, adiponectin, low-density lipoprotein, and 8-isoprostane.

43 a significant increase in total, low-density lipoprotein, and high-density lipoprotein (HDL) choleste

44 s of total cholesterol (TC), TG, low-density lipoprotein, and high-density lipoprotein were measured.

45 significant reductions in total, low-density lipoprotein, and non-high-density lipoprotein cholestero

46 ic and diastolic blood pressure, low-density lipoprotein- and total cholesterol, triglycerides, fasti

47 eb (DeltaIEC) mice exhibited lower levels of lipoprotein ApoA1 expression, which is downregulated in

48 the production rate of intermediate-density lipoprotein-apoB (P=0.043) and LDL-apoB (P<0.001), which

49 poprotein B-100 (apoB), intermediate-density lipoprotein-apoB, and LDL-apoB in 81 healthy, normolipid

50 hospholipids occurring in cell membranes and lipoproteins are converted into oxidized phospholipids (

51 riglyceride availabiity for very low density lipoprotein assembly and allows homeostatic control of s

52 ized efficiently to provide triglyceride for lipoprotein assembly and secretion from the sER.

53 h-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 were measured 1

54 ed with absent enzymatic activity of soluble lipoprotein-associated phospholipase A2; at CYP2F1, with

55 explaining the cardioprotective role of the lipoprotein beyond quantitative HDL cholesterol levels.

56 small intestine, sites for triglyceride-rich lipoprotein biogenesis and export.

57 y validated a new role for phosphatase 1G in lipoprotein biology.

58 esterol (LDL-C) <160 mg/dl, and high-density lipoprotein cholesterol >/=40 mg/dl.

59 o had residual cholesterol risk (Low-density lipoprotein cholesterol >100 mg/dL).

60 with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1 mmol/L in co

61 ters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin therapy), bl

62 erapies, including patients with low-density lipoprotein cholesterol <70 mg/dl.

63 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) remained signifi

64 holesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and borderline

65 (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), high low-densit

66 holesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein

67 cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-densit

68 Pravastatin lowered low-density lipoprotein cholesterol (change in SD units [95% confide

69 ferential responses in total and low-density lipoprotein cholesterol (decreased in LFHC group only),

70 emic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also considered to be

71 protein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either directly mea

72 Differences in mean high-density lipoprotein cholesterol (HDL-C), LDL-C, and apolipoprote

73 cluding total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein

74 as hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C).

75 sociated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685; P=8.1E-26 an

76 significantly higher levels of high density lipoprotein cholesterol (HDLc) were observed in individu

77 reased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC group only).

78 For low-density lipoprotein cholesterol (LDL) of 130-159 mg/dL, AMI rate

79 l, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl, and high-den

80 Serum low-density lipoprotein cholesterol (LDL-C) and high-density lipopro

81 Increased serum levels of low-density lipoprotein cholesterol (LDL-C) are an independent risk

82 ting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation.

83 ibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55% to 75%.

84 ients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite use of st

85 protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing

86 the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovascular events

87 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when

88 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG).

89 evated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in o

90 essed in the liver and regulates low-density lipoprotein cholesterol (LDL-C).

91 regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C).

92 ype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cholesterol (TC

93 scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role i

94 schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05), smoking (r

95 fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein

96 lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol [TC])

97 /kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patient populatio

98 ificant variants associated with low-density lipoprotein cholesterol and coronary heart disease at AP

99 inment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivity C-reactive

100 was positively associated with high-density-lipoprotein cholesterol and intakes of polyunsaturated f

101 tive exposure to lower levels of low-density lipoprotein cholesterol are not associated with neurocog

102 acebo in individuals with normal low-density lipoprotein cholesterol but increased C-reactive protein

103 wer median time-weighted average low-density lipoprotein cholesterol compared with placebo/simvastati

104 , including variants involved in low-density lipoprotein cholesterol concentrations, schizophrenia, a

105 hite blood cell count and lower high-density lipoprotein cholesterol in men, and with higher BMI and

106 e of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-146a in BM-d

107 -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [95% CI, -4.3

108 de level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, and 7%), use of

109 al rates did not vary by patient low-density lipoprotein cholesterol level nor statin use.

110 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 100 mg/dL.

111 reductions in blood pressure and low-density lipoprotein cholesterol levels and improvements in measu

112 price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 80 mg/dL.

113 ow-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyceride levels,

114 pid-lowering medication use, and low-density lipoprotein cholesterol levels.

115 , 8-37; P=0.004) despite similar low-density lipoprotein cholesterol lowering.

116 itiation of statin treatment for low-density lipoprotein cholesterol reduction in children with HeFH.

117 ion, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribing appropriat

118 its estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials w

119 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lower-carbohydra

120 ntervention, and higher level of low-density lipoprotein cholesterol were independent predictors of e

121 Low-density lipoprotein cholesterol(LDL-C) is a well established met

122 ers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical variables (C) (sm

123 ained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than increases in HDL-C

124 ties (high fasting glucose, low high-density lipoprotein cholesterol, and high triglyceride levels an

125 sm, educational attainment, and high-density lipoprotein cholesterol, and significant negative geneti

126 inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently unclear whe

127 scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery disease, C-reac

128 able analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and h

129 of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and body mass ind

130 lood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose, fasting

131 plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high-sensitivity

132 ve biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-reactive protei

133 on quantitative trait loci for a low-density lipoprotein cholesterol-related differentially methylate

134 es potent statin therapy and low low-density lipoprotein cholesterol.

135 to hypertriglyceridemia and low high-density lipoprotein cholesterol.

136 ially improve triglycerides and high-density lipoprotein cholesterol.

137 th hypertriglyceridemia and low high-density lipoprotein cholesterol.

138 e was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase in CEC and

139 scular disease (CVD) context and low density lipoprotein-cholesterol concentrations within a saturate

140 inverse association of FT4 with low-density lipoprotein-cholesterol.

141 al, HR-corrected QT interval or high-density lipoprotein-cholesterol.

142 The length of Braun's lipoprotein determines periplasmic width by tethering th

143 osure of macrophages to oxidized low-density lipoprotein downregulated LKB1 in vitro.

144 ork, we characterize PelC, an outer membrane lipoprotein essential for Pel production.

145 These lipoproteins facilitate Abeta42 transport more efficient

146 ly(I.C) and flagellin but not with synthetic lipoprotein (fibroblast-stimulating lipoprotein 1 [FSL-1

147 Triglyceride-rich lipoprotein fractions of plasma were isolated and extrac

148 s are inconsistent and it is unclear whether lipoprotein function is affected.

149 ulin as well as fasting triglycerides, blood lipoproteins, HbA1c, and body weight.We included 14 comp

150 irculation and transferred from high density lipoprotein (HDL) - a main carrier of cholesterol in the

151 ssociations were independent of high-density lipoprotein (HDL) and non-HDL cholesterol, and extended

152 The causal role of high-density lipoprotein (HDL) cholesterol in cardioprotection has be

153 holesterol levels and increases high-density lipoprotein (HDL) cholesterol levels.

154 l, low-density lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in the total-to-H

155 ndex (BMI), C-reactive protein, high-density lipoprotein (HDL) cholesterol, forced expiratory volume,

156 olic risk-factor profile [lower high-density lipoprotein (HDL) cholesterol, higher total homocysteine

157 lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides at a gen

158 BMI), waist circumference (WC), high-density lipoprotein (HDL) cholesterol, triglycerides, fat mass (

159 r hours post-MI measurements of high-density lipoprotein (HDL) triglycerides (HDL-TG) predicted LVEF

160 %-23% in eQTLs, 35% in GWASs of high-density lipoprotein (HDL), and 23% in GWASs of schizophrenia.

161 ver) is terminated by selective high density lipoprotein (HDL)-cholesteryl ester (CE) uptake, mediate

162 when present on the surface of high-density lipoprotein (HDL).

163 erol concentrations in high- and low-density lipoproteins (HDL and LDL) particles measured by standar

164 SR-BI is the main receptor for high density lipoproteins (HDL) and mediates the bidirectional transp

165 anti-atherogenic properties of high-density lipoproteins (HDL) is unknown.

166 Beneficial effects of high-density lipoproteins (HDL) seem altered in patients with symptom

167 g brain (apoE) and circulating (high-density lipoprotein, HDL) synergize to facilitate Abeta transpor

168 The biological functions of high-density lipoproteins (HDLs) contribute to explaining the cardiop

169 accumulation of apolipoprotein-B-containing lipoproteins, immune and vascular wall cells, and extrac

170 human ANGPTL3 reduced levels of atherogenic lipoproteins in humans.

171 ic activity decrease pro-atherogenic remnant lipoproteins in hyperlipidemic mice.

172 osclerosis and reduced levels of atherogenic lipoproteins in mice.

173 We show that lipoproteins including brain (apoE) and circulating (hig

174 nt, indicating their origin from low-density lipoprotein, intermediate-density lipoprotein, very-low-

175 The presence of the partner SusD-like lipoprotein is the major feature that distinguishes SusC

176 bolic risk-factor profile [lower low-density lipoprotein (LDL) cholesterol and triglycerides] and low

177 International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more than statin th

178 ective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels.

179 these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use

180 be associated with at least 1 of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein

181 9), a target for the lowering of low-density lipoprotein (LDL) cholesterol.

182 Although sequence analysis of low-density lipoprotein (LDL) receptor (LDLR) mRNA did not reveal an

183 To this end, the low-density lipoprotein (LDL) receptor was targeted for degradation

184 thereby upregulating the hepatic low-density lipoprotein (LDL) receptors and increasing the clearance

185 t electronegative subfraction of low-density lipoprotein (LDL), L5, is correlated with QTc prolongati

186 Egg yolk low density lipoprotein (LDL)/polysaccharide nanogels are newly expl

187 l responses of purified low and high density lipoproteins (LDL and HDL, respectively) were first indi

188 olesterol derived from uptake of low-density lipoproteins (LDL) and synthesis.

189 Low-density lipoproteins (LDLs) are a class of nanocarriers for the

190 high levels of damaged modified low-density lipoproteins (LDLs), generating macrophage foam cells.

191 disease multiple sclerosis (MS), reports on lipoprotein level alterations are inconsistent and it is

192 en after accounting for baseline low-density lipoprotein level, statin exposure continued to be assoc

193 ts after accounting for baseline low-density lipoprotein level.

194 In summary, lipoprotein levels and function are altered in RRMS pati

195 tion sequences: chr16:70790626 (high-density lipoprotein levels beta -1.71 (SE 0.25), P=1.57 x 10(-11

196 a known regulator of circulating low-density lipoprotein levels in humans, as a novel target of miR-1

197 ent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL (<55 mg/dL for wom

198 CETP and HMGCR scores, changes in lipid and lipoprotein levels, and the risk of cardiovascular event

199 After accounting for baseline low-density lipoprotein levels, persons who filled prescriptions for

200 ALE: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like lipoprotein and important cardiovascula

201 PPARgamma coactivator 1beta (PGC1beta), and lipoprotein lipase (LPL) were among the up-regulated gen

202 asma apoE, but neither significantly altered lipoprotein lipase and cholesteryl ester protein mass or

203 assess how circulating metabolites, such as lipoprotein lipids, fatty acids, amino acids, and glycol

204 ediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylomicron remnants.

205 n synthase PBP1A requires the outer membrane lipoprotein LpoA for constructing a functional peptidogl

206 his distance by increasing the length of the lipoprotein Lpp destroyed signalling, whereas simultaneo

207 OM is tethered to the peptidoglycan via the lipoprotein, Lpp.

208 Lipoprotein maturation requires the sequential activity

209 .5 mg/dl, 95% CI -9.5, -7.4) and low-density lipoprotein (MD -2.4 mg/dl, 95% CI -3.4, -1.3).

210 interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chain amino acids (e.

211 of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains to be fully evaluated.

212 on loci identify genes involved in lipid and lipoprotein metabolism, substrate transport and inflamma

213 cterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.

214 otein C-III (apoC-III) is a key regulator of lipoprotein metabolism.

215 Here we demonstrate that high-density lipoprotein-mimicking nanodiscs coupled with antigen (Ag

216 The OM lipoprotein MlaA performs the first step in this process

217 Lipoprotein nanodiscs are ideally suited for native mass

218 ere the association of HCV virions with host lipoproteins occurs.

219 e and insulin, haemoglobin A1c, high-density lipoprotein or blood pressure.

220 d meat/d does not influence blood lipids and lipoproteins or blood pressures.

221 holesterol crystals and oxidized low-density lipoproteins (ox-LDL), potentially by increasing the cel

222 Low-density lipoprotein oxidizability, indicative of the susceptibil

223 he uptake of native and oxidized low-density lipoprotein (oxLDL) by macrophages (Mvarphis) and foam c

224 izes oxidized lipids in oxidized low-density lipoprotein (oxLDL) particles, a process that induces an

225 alize lipids, including oxidized low-density lipoprotein (oxLDL).

226 astrocytes secreted abundant apoE with apoE4 lipoprotein particles less lipidated compared to apoE3 p

227 d inflammasome activation, the extracellular lipoprotein particles may actively enhance atherogenesis

228 Proteomic analysis of isolated extracellular lipoprotein particles revealed that apolipoprotein B is

229 sterolemia leads to immune responses against lipoprotein particles that drive atherosclerosis.

230 reduction in the plasma pool sizes of these lipoprotein particles.

231 b decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerating their ca

232 tor repurposed during infection to fine-tune lipoprotein processing and host responses.

233 iggers a metabolic program that orchestrates lipoprotein processing in brown adipose tissue (BAT) and

234 esonance (NMR) spectroscopy, we analysed the lipoprotein profile of relapsing-remitting (RR) MS patie

235 KB1 reduction caused by oxidized low-density lipoprotein promotes foam cell formation and the progres

236 increasing the length of the stress-sensing lipoprotein RcsF restored signalling.

237 lisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its recycling.

238 These results identify control of lipoprotein receptor abundance by IDOL as a post-transcr

239 d aorta in atherosclerosis-prone low-density lipoprotein receptor deficient (Ldlr(-/-)) mice.

240 ing protein 2 and downregulating low-density lipoprotein receptor expression.

241 DS AND Paradoxically, Ldlr(-/-) (low-density lipoprotein receptor null) mice deficient in miR-146a de

242 ion size was found in Ldlr(-/-) (low-density lipoprotein receptor null) mice transplanted with bone m

243 In parallel, the low-density-lipoprotein receptor plays a predominant role in the cle

244 s analyzed in aortic arches from low density lipoprotein receptor(-/-) mice consuming a high-choleste

245 P2X7(+/+) and P2X7(-/-) low density lipoprotein receptor(-/-) mice were fed a high-cholester

246 an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2 signaling pathwa

247 cted deletion of DNGR-1 in Ldlr (low-density lipoprotein receptor)-deficient mice (Ldlr(-/-)) signifi

248 th the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirmed by a RELN-bind

249 Genetic deletion of a lipoprotein receptor, CD36, reduces macrophage lipid con

250 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger rec

251 nvading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-/-) ) mouse.

252 ecreased hepatic inflammation in low-density lipoprotein receptor-deficient mice on a Western-type di

253 Low density lipoprotein receptor-null (Ldlr(-/-)) mice on a high-fat

254 Low-density lipoprotein receptor-related protein 1 (LRP-1) is a scav

255 he endocytic scavenger receptor, low-density lipoprotein receptor-related protein 1 (LRP1).

256 s mRNA and protein expression of low density lipoprotein receptor-related protein 2 and alpha-synucle

257 dentified novel functions of the low-density lipoprotein receptor-related protein 4-muscle-specific k

258 s a ternary complex with the Wnt co-receptor Lipoprotein receptor-related protein 6 (LRP6).

259 mbospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1).

260 pathway that apparently requires low-density lipoprotein receptor-related protein-1 (LRP1).

261 regulating neuronal migration by binding to lipoprotein receptors.

262 y relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL), polymeric micelles ([S]-PM), and

263 d consequences of defective very low-density lipoprotein secretion.

264 Lipoproteins serve essential roles in the bacterial cell

265 The particles originate from plasma lipoproteins, show signs of lipolytic modifications, and

266 o directly represses lspB, a gene encoding a lipoprotein signal peptidase whose expression appears de

267 55 proteins contained the lipoprotein signal peptide recognition site of signal pe

268 known about their effects on metabolite and lipoprotein subclass profiles.

269 method simultaneously provides fine-grained lipoprotein subclass profiling and quantification of cir

270 bclasses, with the exception of high-density lipoprotein subclasses, which displayed a more heterogen

271 tion, pravastatin globally lowered levels of lipoprotein subclasses, with the exception of high-densi

272 with lower concentrations of apoB-containing lipoprotein subfractions; at either A3GALT2 or NRG4, wit

273 ranslational modification pathway leading to lipoprotein synthesis involves three enzymes.

274 fHbp is a surface-exposed lipoprotein that binds the negative complement regulator

275 negative bacteria express a diverse array of lipoproteins that are essential for various aspects of c

276 apolipoprotein B component of a low-density lipoprotein through a disulfide bridge to form lipoprote

277 We show that the Braun's lipoprotein tilts and bends, and thereby lifts the cell

278 usceptibility of apolipoprotein B-containing lipoproteins to oxidation, was significantly increased i

279 ed similar laboratory methodology to measure lipoproteins, totaling 2997 incident cases.

280 orm any truly essential mechanistic steps in lipoprotein trafficking.

281 lso increases in the intensities of selected lipoprotein triacylglycerol (1)H NMR signals over those

282 to palmitate of circulating very low-density lipoprotein triglyceride.

283 bserved for extremely large very-low-density lipoprotein triglycerides (odds ratio [OR] = 4.86 per 1

284 g variants in genes in the triglyceride-rich lipoprotein (TRL) clearance pathway that are protective

285 on genotype, or APOE3/E4), triglyceride-rich lipoproteins (TRLs) were isolated at fasting and 4-6 h f

286 (scavenger receptor A), modified low-density lipoprotein uptake and foam cell formation, all of which

287 mechanism by which Akt3 deficiency promotes lipoprotein uptake in macrophages is unknown.

288 We have found previously that increased lipoprotein uptake via the receptor-independent process

289 dent of the glycolytic switch, fatty acid or lipoprotein uptake.

290 ow-density lipoprotein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (

291 he existence of LVPs that cofractionate with lipoproteins, viral proteins, RNA, and vesicular compone

292 Hepatitis C virus (HCV) exists as a lipoprotein-virus hybrid lipoviroparticle (LVP).

293 HCV coopts the secretion of very-low-density lipoprotein (VLDL) for its egress.

294 to-Golgi trafficking of pre-very low-density lipoprotein (VLDL) particles.

295 s on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apoB), intermed

296 CV cell-to-cell spread, but very-low-density lipoprotein (VLDL)-containing mouse serum did not affect

297 Very-low-density lipoproteins (VLDL) is a hallmark of metabolic syndrome

298 The kinetics of apoB in these lipoproteins was studied using a stable isotope infusion

299 G, low-density lipoprotein, and high-density lipoprotein were measured.

300 cal levels of CS were effective at retaining lipoproteins, whose deposition is also found in early CA